Navigation Links
Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172
Date:8/14/2008

ffinity, and the ability to target protein-protein interactions.

NU172 is an aptamer designed to directly inhibit thrombin's ability to stimulate blood clot formation in the setting of medical procedures where human blood is exposed to foreign materials. Specifically, NU172 is being studied for use as a potential short-acting anticoagulant during procedures such as coronary artery bypass graft surgery, kidney dialysis and percutaneous coronary interventions. Data from the Phase 1 trial and preclinical studies suggest that NU172 has the potential to produce rapid and predictable onset and offset of anticoagulation, work in stagnant blood, avoid thrombocytopenia, and has the potential for non-renal clearance.

About Nuvelo and Archemix's Joint Collaborative Effort

In August 2006, Nuvelo expanded its collaboration with Archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, Archemix is responsible for discovery of short-acting aptamers for use in medical procedures, and Nuvelo leads development and worldwide commercialization of these aptamers.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor which has completed Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and NU206, a Wnt pathway modulator in Phase 1 development for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Informati
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
2. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
3. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
4. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
5. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. NewCardio Announces Positive Results From Third Clinical Validation Study
10. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015  AbbVie (NYSE: ABBV ... in its neuroscience and oncology development programs have ... American Academy of Neurology annual meeting in ... 18-25. The accepted abstracts feature results from studies ... investigational treatments in AbbVie,s pipeline. Presentations will include ...
(Date:2/26/2015)... Feb. 26, 2015  Mobility Ventures LLC, an AM ... Bank of America (NYSE: BAC ) that ... financing of the revolutionary MV-1 - - the world,s ... ground up to provide safe and comfortable transportation for ... their loan to purchase a new MV-1 vehicle at ...
(Date:2/26/2015)... -- Every year many millions of donations are obtained ... year after year doctors and the medical profession continue ... to determine the status of heart health in all ... though that technology is over 100 years old, ... (while most patients do not know) that EKG,s, in ...
Breaking Medicine Technology:AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3National Heart Health Month In February 2
... LLC announced today that it has achieved the ... Products Certification for Health Information Line. The accreditation ... nurseline staffed by highly experienced, registered nurses that ... providing immediate clinical support for everyday health issues ...
... England, April 6, 2011 BioWa, Inc. (BioWa) ... they have entered into a license agreement to ... Technology platform for the development of antibody dependent ... OBT intends to use POTELLIGENT® Technology to develop, ...
Cached Medicine Technology:Alere Earns NCQA Health Information Products Certification for Health Information Line 2Oxford BioTherapeutics Licenses BioWa's POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer 2Oxford BioTherapeutics Licenses BioWa's POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer 3
(Date:2/27/2015)... Vancouver, BC (PRWEB) February 27, 2015 ... exciting overnight deals for couples who wanted to spend ... with the opportunity to get a jump on Valentine’s ... meal and stay in one of their luxurious rooms. ... on February 13, inviting guests for a mouthwatering 3 ...
(Date:2/27/2015)... February 27, 2015 Glidewell Laboratories, ... the launch of its CloudPoint™ family ... digital production of monolithic zirconia crowns & bridges, ... of providing the CAD/CAM-produced restorations that doctors demand. ... through which cases can be scanned, managed and ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 ... company that provides vascular, echocardiogram and NCV testing ... be the preferred diagnostic testing provider for young ... coeducational public liberal arts university in Milledgeville, Georgia. ... Wimbledon U collegiate division, include a ...
(Date:2/27/2015)... Over 440,000 patients die annually as a result of ... jet airplanes crashing each day. Now more than ever before, ... to do all they can to stay safe. , Through ... U.S. Surgeon General, discusses the importance of safer hospitals. “It’s ... safety issues to ensure that all our patients are in ...
(Date:2/27/2015)... 27, 2015 Lyophilization has important applications ... as a standard process to stabilize, store and increase ... molecules such as vaccines, antibodies, proteins, enzymes, hormones, ... structure. The global freeze drying market was valued at ... at $2,655.9 million by 2019 at a CAGR of ...
Breaking Medicine News(10 mins):Health News:Victorian Hotel Celebrated Valentine’s Day in 2015 With Unique Overnight Deal 2Health News:Glidewell Laboratories Announces Release of CloudPoint™ FastScan™ and FastDesign™ 2Health News:Glidewell Laboratories Announces Release of CloudPoint™ FastScan™ and FastDesign™ 3Health News:Georgia College Ensures Student-Athletes Are Heart Smart Team Strong; Teams up with Wimbledon Health Partners to Offer Diagnostic Testing 2Health News:Georgia College Ensures Student-Athletes Are Heart Smart Team Strong; Teams up with Wimbledon Health Partners to Offer Diagnostic Testing 3Health News:Dr. Richard Carmona, the 17th U.S. Surgeon General, and IntelliCentrics Raise Awareness in Mediaplanet’s “Patient Safety” Campaign 2Health News:Lyophilization Equipment Market worth $2,655.9 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Lyophilization Equipment Market worth $2,655.9 Million by 2019 - New Research Report by MarketsandMarkets 3
... , , Provides oral regime for ... SILVER SPRING, Md. , Jan. 29 The ... combination with Femara (letrozole) to treat hormone positive and HER2-positive ... is indicated. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , ...
... Over a two and half year period, beginning in 2005 ... office began reviewing marketing applications, a total of 60 new ... approved, according to a new article published online January 29 ... To provide an overview of recent regulatory actions ...
... Kentucky researcher is investigating respiratory weakness as a factor ... be testing new treatments that could improve long-term patient ... Supinski, professor and vice chair of research for the ... College of Medicine, was awarded a highly competitive, two-year, ...
... than blacks, researchers find , FRIDAY, Jan. 29 (HealthDay News) ... disease in the United States is more common in the ... as likely to develop the disease as blacks and Asians. ... 36 million Medicare recipients, are the first to take a ...
... ... 29   Following is the National Council on Disability,s monthly bulletin ... charge and at NCD,s award-winning Web site ( http://www.ncd.gov ), brings you ... the NCD listserv, go to http://listserv.access.gpo.gov , click on "Online mailing ...
... Va., Jan. 29 Care Net , ... support to pregnant women, was drawn into the Tebow Super ... Fox News.  Care Net President Melinda Delahoyde said ... pregnancy centers provide free services to 1.9 million people every ...
Cached Medicine News:Health News:FDA Expands Use of Approved Breast Cancer Drug 2Health News:FDA Expands Use of Approved Breast Cancer Drug 3Health News:Kentucky research looks at respiratory weakness in ICU morbidity 2Health News:Parkinson's More Common in Northeast, Midwest 2Health News:National Council on Disability Monthly Bulletin for January 2010 2Health News:National Council on Disability Monthly Bulletin for January 2010 3Health News:National Council on Disability Monthly Bulletin for January 2010 4Health News:National Council on Disability Monthly Bulletin for January 2010 5Health News:National Council on Disability Monthly Bulletin for January 2010 6Health News:National Council on Disability Monthly Bulletin for January 2010 7Health News:National Council on Disability Monthly Bulletin for January 2010 8Health News:National Council on Disability Monthly Bulletin for January 2010 9Health News:Care Net Calls Tebow Ad Opponents' Slam of Pregnancy Centers 'Nonsensical' 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: